Zarix begins Phase III

Zarix (Berwyn, Penn.) began an international Phase III trial of its Thymitaq nolatrexed (AG337) to treat hepatocellular carcinoma. Zarix licensed Thymitaq from Agouron Pharmaceuticals (La Jolla, Calif...